[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Thomas Hope\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,91,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100589951","phase-2-comparison-of-i-124-petct-for-the-diagnosis-of-thyroid-cancer-100589951",false,"NCT06961084","Comparison of I-124 PET\u002FCT for the Diagnosis of Thyroid Cancer","Comparison of I-124 PET\u002FCT to I-123 Whole Body Imaging for the Diagnosis of Thyroid","Inclusion Criteria:\n\n1. Age \\>= 13 years.\n2. Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.\n3. Meeting criteria for one of the following two populations:\n\n   1. American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.\n   2. Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.\n4. Undergone total thyroidectomy.\n5. Planned I-123 imaging within 45 days after enrollment.\n6. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.","ALL","13 Years",{"count":19,"type":20},62,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.",[26],"Thyroid Cancer",[28],"Imaging Studies","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2025-12-04",{"date":37,"type":20},"2028-04-01",{"name":39,"class":40},"Thomas Hope","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100410202","phase-1-imaging-of-solid-tumors-using-fap-2286-100410202","NCT04621435","Imaging of Solid Tumors Using FAP-2286","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Histopathologically confirmed solid tumors in one of the following cohorts:\n\n   a. Cohort 1 (n=11): measurable disease is not required for this cohort.\n\n   i. Agnostic to tumor type.\n\n   b. Cohort 2 (n=95): Metastatic disease present on conventional imaging defined as having RECIST 1.1 measurable disease or multiple bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.\n\n   i. Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, colon cancer, or other cancer type.\n\n   c. Cohort 3 (n=85): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.\n\n   i. Participants can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Participants may also be imaged after therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and\u002For prognosis.\n\n   ii. Pathologically confirmed head and neck cancer, bladder cancer, or other cancer type.\n3. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.","18 Years",{"count":50,"type":20},191,[52],"PHASE1","This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.",[55,56],"Solid Tumors, Adult","Metastatic Cancer",[58,59,60],"PET","68Ga-FAP-2286","64Cu-FAP-2286","2026-06-02",{"date":63,"type":33},"2026-06-04",{"date":65,"type":33},"2020-12-14",{"date":67,"type":20},"2026-12-31",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100552549","fluoroethyltyrosine-for-the-evaluation-of-intracranial-neoplasm-100552549","NCT06474533","Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm","Inclusion Criteria:\n\n* Presence or suspicion of intracranial neoplasm in two populations:\n\n  * Population 1: Participants after primary treatment (radiation therapy and\u002For surgery) with suspicion of recurrence on MRI.\n  * Three sub-populations will be considered:\n\n    * Recurrent metastatic lesions.\n    * Recurrent high-grade gliomas (Grades 3 and 4).\n    * Recurrent low-grade gliomas (Grade 2).\n  * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.\n* Age \\> 3 years.\n\nParticipants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.\n\nExclusion Criteria:\n\n* Participants with known incompatibility to PET or Computerized tomography (CT)\u002Fmagnetic resonance imaging (MRI) scans.\n* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.\n\n  * Sedation or anesthesia can be used for participants who cannot tolerate the exam.","4 Years",{"count":77,"type":20},199,"OBSERVATIONAL","This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.",[81],"Intracranial Neoplasm",[28],"2026-03-30",{"date":85,"type":33},"2026-04-03",{"date":87,"type":33},"2024-06-21",{"date":89,"type":20},"2028-08-31",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":48,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100597119","phase-1-comparison-of-177lu-psma-617-and-225ac-psma-617-100597119","NCT07054346","Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 in a Prostatectomy Model (LUTACT Trial)","LUTACT","Inclusion Criteria:\n\n1. Histologically confirmed prostate adenocarcinoma.\n2. Willing to undergo prostatectomy with or without lymph node dissection, and candidate for prostatectomy as determined by urologic oncology.\n3. High-risk disease as defined as meeting 1 or more of the 3 following criteria:\n\n   1. Gleason score of 4+5 disease or higher.\n   2. Pelvic nodal metastases on PSMA PET.\n   3. Extracapsular extension or seminal vesicle invasion on MRI.\n4. No evidence of distant metastatic disease as determined by PSMA PET. Nodal disease below the iliac bifurcation (clinical stage N1) is allowed.\n5. Maximum Standardized Uptake Value (SUVmax) in the primary tumor greater than 10 on PSMA PET using Gallium-68 (68Ga)-PSMA-11 or piflufolastat F 18 (18F-DCFPyL).\n6. Target tumor in the prostate measuring greater than 1.5 cm on MRI.\n7. Age ≥18 years.\n8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%),\n9. Demonstrates adequate organ function as defined below:\n\n   1. Platelets ≥100,000\u002FmcL, independent of transfusions or growth factors within 3 months of treatment start.\n   2. Hemoglobin ≥10 g\u002FdL, independent of transfusions or growth factors within 3 months of treatment start.\n   3. Absolute Neutrophil Count (ANC) ≥1,500\u002Fmicroliter (mcL).\n   4. Creatinine clearance Glomerular filtration rate (GFR) ≥ 60 mL\u002Fmin\u002F1.73 m\\^2 , calculated using the Cockcroft-Gault equation.\n   5. Albumin ≥2.5 g\u002FdL.\n   6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN.\n   7. Total bilirubin (TBIL) ≤2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 x ULN is permitted.\n10. Ability to understand and the willingness to sign a written informed consent document.\n11. Participants must provide consent to comply to recommended radioprotection precautions during study.\n12. Participants must use adequate contraception and not donate sperm while on study drug and for at least 14 weeks after the last study treatment.\n\nExclusion Criteria:\n\n1. Has received prior prostate cancer therapy.\n\n   a. Prior 5-alpha reductase inhibitors (e.g. finasteride, dutasteride) allowed if discontinued at least 3 weeks prior to treatment start.\n2. Has participated in a study of an investigational therapeutic product and received study treatment or used an investigational device within four weeks of the first dose of treatment.\n3. Dry mouth that impacts the eating of food (i. e. requiring mouthwash prior to eating).\n4. Concurrent serious (as determined by the principal investigator) medical conditions including but not limited to New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.\n5. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.\n6. Individuals with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Prior external beam radiation therapy (EBRT) to the prostate or prostate bed.\n\nAdditional exclusion criteria applicable only to participants undergoing intraarterial administration of PSMA RLT:\n\n1. Severe allergy to iodinated contrast.\n2. Severe atherosclerosis from prior CT imaging study, or greater than 10 pack-year smoking history if no prior imaging available.","MALE",{"count":101,"type":20},45,[52],"There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.",[105,106,107,108,109],"Prostate Cancer","Prostate Cancer (Diagnosis)","High-risk Prostate Cancer","Localized Prostate Carcinoma","Very High Risk Prostate Carcinoma",[111],"Radioligand Therapy","2026-03-26",{"date":114,"type":33},"2026-04-01",{"date":116,"type":33},"2025-07-08",{"date":118,"type":20},"2028-04-30",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":134,"locationsCount":4},"100609718","expanded-access18f-fluorocholine-for-the-detection-of-parathyroid-adenomas-100609718","NCT07218224","Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas","Inclusion Criteria:\n\n1. Age ≥ 13 years.\n2. Evidence of primary hyperparathyroidism.\n3. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1\\. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.","EXPANDED_ACCESS","This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.",[129],"Parathyroid Adenomas","AVAILABLE","2025-10-14",{"date":133,"type":33},"2025-10-20",{"name":39,"class":40},""]